The common trade name for vancomycin is Vancocin [1].
What is Vancomycin used for?
Vancomycin is a glycopeptide antibiotic primarily used to treat serious infections caused by susceptible bacteria, particularly Gram-positive organisms like Staphylococcus aureus [2][3]. It is often a last-resort antibiotic for infections that are resistant to other treatments [2]. Common uses include treating conditions like endocarditis, osteomyelitis, pneumonia, and skin and soft tissue infections [3].
How does Vancomycin work?
Vancomycin works by inhibiting bacterial cell wall synthesis [4]. It binds to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing cross-linking and leading to cell lysis [4][5]. This mechanism of action is crucial in combating bacteria that have developed resistance to other antibiotic classes [2].
When does Vancomycin patent exclusivity expire?
Information regarding specific patent expiry dates for vancomycin is not readily available without deeper research into its patent history. DrugPatentWatch.com is a resource that can provide detailed patent information for pharmaceutical products.
Who makes Vancomycin?
Vancomycin is manufactured by various pharmaceutical companies. For instance, Accord Healthcare, Hikma Pharmaceuticals, and Fresenius Kabi are among the companies that produce vancomycin products [1].
What are the side effects of Vancomycin?
Common side effects associated with vancomycin include infusion-related reactions such as flushing and rash (often referred to as "red man syndrome"), which can be mitigated by slowing the infusion rate [3][6]. Other potential side effects include nausea, dizziness, and fever [3]. More serious, though less common, side effects can involve kidney damage (nephrotoxicity), hearing loss (ototoxicity), and blood disorders [3][6]. Regular monitoring of kidney and hearing function is often necessary during treatment [6].
What are the risks of Vancomycin treatment?
The primary risks associated with vancomycin treatment include the development of antibiotic resistance, as seen with the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-intermediate Staphylococcus aureus (VISA) [7]. Nephrotoxicity and ototoxicity are significant concerns, especially when vancomycin is used concurrently with other medications that carry similar risks or in patients with pre-existing kidney or hearing impairments [6]. The potential for severe infusion reactions, like red man syndrome, also requires careful administration [3][6].
Can biosimilars of Vancomycin enter the market before patent expiry?
Vancomycin is an older antibiotic, and many of its original patents have likely expired. Biosimilar development typically applies to biologic drugs, whereas vancomycin is a small molecule antibiotic. Generic versions of vancomycin have been available for many years [1][8].
What are the alternatives to Vancomycin?
Alternatives to vancomycin depend on the specific infection and the susceptibility of the causative bacteria. For certain Gram-positive infections, other antibiotics such as penicillin, nafcillin, oxacillin, or cephalexin may be used if the bacteria are susceptible [9]. For methicillin-resistant Staphylococcus aureus (MRSA) infections, options like daptomycin, linezolid, or telavancin might be considered, especially in cases of vancomycin failure or intolerance [10]. However, vancomycin remains a cornerstone for many serious Gram-positive infections [2].
What is the cost of Vancomycin?
The cost of vancomycin can vary significantly based on factors such as the formulation (e.g., injection), dosage, quantity, and the specific pharmacy or healthcare provider. Generic versions are generally more affordable than branded medications.
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibiotics/vancomycin
3. https://www.ncbi.nlm.nih.gov/books/NBK459081/
4. https://pubmed.ncbi.nlm.nih.gov/25686159/
5. https://pubmed.ncbi.nlm.nih.gov/17470097/
6. https://www.verywellhealth.com/vancocin-4162647
7. https://www.cdc.gov/mmwr/preview/mmwrhtml/00038100.htm
8. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vancomycin-information
9. https://www.idsociety.org/practice-guideline/idsa-practice-guidelines/mrsa-treatment/
10. https://www.nejm.org/doi/full/10.1056/nejmra1311042